X

Trial Profile

Doxorubicin-Transdrug in Advanced HepatoCellular Carcinoma A Randomized, Multicenter Phase 2-3 Study.

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 11 Aug 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doxorubicin (Primary) ; Antineoplastics
Indications Liver cancer
Focus Therapeutic Use
Acronyms DOTAHCC1
Sponsors BioAlliance Pharma

Most Recent Events

11 Aug 2017 This trial has been Discontinued in Belgium, according to European Clinical Trials Database.
11 Aug 2014 Status changed from suspended to completed as reported by European Clinical Trials Database record.
06 Sep 2011 Preliminary results of 28 evaluable patients (of a planned 50) were presented at the annual congress of the International Liver Cancer Association, as reported in a BioAlliance Pharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com